Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback